Journal of Diabetes Science and Technology

embecta sponsors educational symposium at ATTD 2023

Retrieved on: 
Wednesday, February 22, 2023
Type 2 diabetes, Research institute, Quality of life, University, MD, DO, Prince Sultan Advanced Technology Research Institute, Treatment, Journal, Patient, Legal nurse consultant, Journal of Diabetes Science and Technology, PWD, Central European Time, EMBC, ATTD, Pharmaceutical industry, Diabetes

PARSIPPANY, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host an industry-sponsored symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference on Friday, February 24, 2023, at 10:40 a.m. Eastern Standard Time / 4:40 p.m. Central European Time.

Key Points: 
  • PARSIPPANY, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host an industry-sponsored symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference on Friday, February 24, 2023, at 10:40 a.m. Eastern Standard Time / 4:40 p.m. Central European Time.
  • “People with diabetes must take a very hands-on role in the day-to-day management of their healthcare,” says Henry Anhalt, DO, Chief Medical Officer, embecta.
  • “The co-creation of treatment plans that are centered around the unique circumstances and needs of people living with diabetes is imperative to improving care.
  • ATTD 2023 is taking place at the CityCube Berlin, Berlin, Germany.

Study Results Published in Journal of Diabetes Science and Technology Show Sustained Clinically Significant Improvements in Glycemic Control in Over 144,000 People with Diabetes Using a Smart Blood Glucose Meter and Mobile App

Retrieved on: 
Tuesday, January 31, 2023
Real-World Evidence, Glycemia, OneTouch Ultra, Overalls, Mobile diabetes screening initiative, American Diabetes Association, Diabetes, Glucose meter, Global Medical Device Nomenclature, Journal of Diabetes Science and Technology, Metre, Smartphone, Blood, LifeScan, Patient, Data, BGM, Research, Medical device, Satellite navigation device, Mobile phone, Limestone, Safety, T1D

The full publication is available with open access at: Journal of Diabetes Science and Technology (JDST), Improved Glycemic Control Using a Bluetooth®-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes .

Key Points: 
  • The full publication is available with open access at: Journal of Diabetes Science and Technology (JDST), Improved Glycemic Control Using a Bluetooth®-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes .
  • These 180-day findings expand on the results from a 90-day timeframe first presented at the 82nd Scientific Sessions of the American Diabetes Association in June 2022.
  • The real-world data provides insights into improved glycemic metrics among people with diabetes using a Bluetooth connected BGM together with a diabetes management digital app - in this study, patients used the OneTouch Verio Flex® meter and OneTouch Reveal® app.
  • "The overwhelming majority, approximately 95%, of people with diabetes who monitor their blood glucose rely on cost-effective blood glucose monitoring with a blood glucose meter.

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.

Retrieved on: 
Tuesday, November 15, 2022
Conference, Health, Pain, U.S. Securities and Exchange Commission, The ReVe Festival: Day 2, Security (finance), Journal, Solution, Infection, Freedom, Partnership, Awareness, Survival rate, Diabetes, NYSE, Insulin, EVP, Health risk assessment, Technology, Patient, Risk, Clinical trial, Journal of Diabetes Science and Technology, PMID, EPUB, Medical device, Pharmaceutical industry, Risk management, Medtronic

DUBLIN, Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.

Key Points: 
  • An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.
  • The Medtronic Extended infusion set uses advanced materials that helpreduce insulin preservative loss and maintain insulin flow and stability to double the wear time of an infusion set.
  • "With the Medtronic Extended infusion set, these life interruptions are reduced with an innovation that doubles the wear."
  • The Medtronic Extended infusion set was developed in partnership with Convatec Infusion Care, the world's largest producer of infusion sets.

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Retrieved on: 
Friday, June 3, 2022
Consensus, Ketoacidosis, Kidney, Hospital, Life, Continuous glucose monitor, Prenatal nutrition, Diabetic ketoacidosis, DKA, Food, JDRF, CGM, Interpretation, Blood, Part, FreeStyle, Utility, Method, Journal of Diabetes Science and Technology, Risk, Review, Technology, Clinical case definition, NYSE, Pivotal, Adoption, Incidence, Diagnosis, Ketone, Heart, SGLT, CKM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Integration, Glucose, Medical device, Pharmaceutical industry, Frankincense, Fine chemical, Diabetes, Patient

"We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.

Key Points: 
  • "We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.
  • Recent studies show continuous ketone monitoring (CKM) could help prevent DKA.3 With continuous monitoring, rising ketone levels can be detected early, as a warning of impending ketoacidosis, and inform care so that DKA does not develop.
  • Abbott is already conducting clinical studies on the glucose-ketone monitoring system.
  • Abbott plans to partner with leading insulin pump manufacturers to make the dual monitoring system interoperable with insulin delivery systems.

Welldoc's BlueStar Named 2022 "Best Overall Connected Healthcare Solution" in 2022 MedTech Breakthrough Awards Program

Retrieved on: 
Thursday, May 5, 2022
Patient engagement in Canada, EHR, Terrin, Global health, Blue star, What Comes Next, Fitness, Twitter, Journal of Diabetes Science and Technology, Heart failure, Diabetes, Patient, Exercise, Partnership, Hypertension, FDA, Intervention, Leadership, MHealth, Adult, Telehealth, Health, Medtech, Medical device, LinkedIn, MM, Electronic health record, Self-management, Solution, Technology, CEO, Research, AI, Genomic and Medical Data, Pharmaceutical industry

LOS ANGELES, May 5, 2022 /PRNewswire-PRWeb/ -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, today announced that Welldoc®, a digital health leader revolutionizing chronic care, has been selected as winner of the "Best Overall Connected Healthcare Solution" award in the sixth annual MedTech Breakthrough Awards program.

Key Points: 
  • The platform includes an AI-driven digital coaching app that offers personalized, actionable guidance throughout an individual's chronic care journey.
  • Together, we are building more comprehensive chronic care programs, focused on prevention, self-management, connected care, and total health."
  • "Welldoc is a pioneering innovator in delivering 'breakthrough' connected healthcare solutions to provide these insights.
  • The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more.

New Studies Demonstrate Clinical Benefits of Patient- and Provider-Supportive Technology in Diabetes Management

Retrieved on: 
Wednesday, April 27, 2022
ATTD, Health, T1D, Technology, OTR, Journal of Diabetes Science and Technology, Adoption, Telephone, Obesity, COVID-19, Blood, Bluetooth, Research, Weight loss, Diagnosis, Caregiver, A1C, Treatment, Patient, Conference, Type 2 diabetes, Telehealth, Overweight, T2D, HCPS, Global Medical Device Nomenclature, BGM, Solution, American Association of Clinical Endocrinologists, Method, Journal, Meal, Multimedia, International Conference on Information Systems Security and Privacy, Quality of life, HCP, Prevalence, COVID, OneTouch Ultra, Trust, Honda advanced technology, Medical device, Pharmaceutical industry, Satellite navigation device, Mobile phone, Safety, Acnalbasac Noom, LifeScan, Diabetes

MALVERN, Pa., April 27, 2022 /PRNewswire/ -- LifeScan, a world leader in blood glucose monitoring, announced today the presentation of three studies showing the value of app-based technology in improving diabetes management. The three studies, presented at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), examined the use of different technologies in various patient populations, and all similarly concluded that a clear benefit was observed for healthcare providers and patients with diabetes.

Key Points: 
  • A second study analyzed the benefit of 16 weeks of free access to Noom's app-based weight loss program for people living with type 2 diabetes.
  • "Our goal at LifeScan is to offer people living with and treating diabetes the digital tools and connected solutions that can make its management easier and more successful.
  • Blood glucose monitors (BGM) are vital for over 95% of people with diabetes who monitor their blood glucose.
  • The aim was to understand the impact digital diabetes management solutions, like OTR, had during the pandemic.

Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism

Retrieved on: 
Wednesday, October 27, 2021
Research, Diabetes, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Research, Sugar, Molecular biology, Pathology, Patient, Insulin, Vanderbilt University School of Medicine, Journal of Diabetes Science and Technology, Fats, Medicine, Technology, CEO, Lists of diseases, Attention, Health, Metabolism, Publication, Microdeletion syndrome, Journal, Diabetes, Pharmaceutical industry

Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model.

Key Points: 
  • Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model.
  • The company believes the Metabolic Balance Model is one of the most comprehensive frameworks in this field.
  • The article, titled A Gut-Centric Model of Metabolic Homeostasis , is published in the October issue of the Journal of Diabetes Science and Technology.
  • Fractyl Health is dedicated to developing novel treatments for metabolic diseases based on innovative scientific insights into the root causes of metabolic dysfunction.

New Study Shows CGMs, Paired with Mobile Health App, Can Significantly Improve Glucose Regulation

Retrieved on: 
Thursday, June 17, 2021
Diabetes, Medicine, Clinical medicine, Health, Prediabetes, Blood glucose monitoring, Type 1 diabetes, Type 2 diabetes, Continuous glucose monitor, Glucose test, Journal of Diabetes Science and Technology

"Half of the adult U.S. population, some 122 million people, have diabetes or prediabetes," notes January AI founder and CEO Noosheen Hashemi.

Key Points: 
  • "Half of the adult U.S. population, some 122 million people, have diabetes or prediabetes," notes January AI founder and CEO Noosheen Hashemi.
  • "With AI, we have an unprecedented opportunity to help them figure out what in their daily habits is working and what needs tweaking.
  • January AI also announces today that its scientific study "Improvement in glucose regulation using a digital tracker and continuous glucose monitoring in healthy adults and those with Type 2 Diabetes" has been published in Diabetes Therapy.
  • "Diabetes is a health problem greater than COVID, and we need advanced technologies like these to help get this endemic under control and improve people's lives."

Vida Health’s Virtual Diabetes Program Achieves Meaningful Clinical Outcomes in Reducing HbA1c

Retrieved on: 
Wednesday, June 2, 2021
Health, Diabetes, Hospitals, General Health, Pharmaceutical, Biotechnology, Diabetes, Clinical medicine, Medicine, Health, Diabetes management, Glycated hemoglobin, Type 2 diabetes, Fructosamine, Journal of Diabetes Science and Technology

New research published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes) shows clinically meaningful reductions in Hemoglobin A1c (HbA1c) levels for participants enrolled in Vida Health s virtual diabetes management program.

Key Points: 
  • New research published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes) shows clinically meaningful reductions in Hemoglobin A1c (HbA1c) levels for participants enrolled in Vida Health s virtual diabetes management program.
  • The studys findings suggest that Vidas program represents an accessible, scalable, and effective solution to type 2 diabetes management and improved HbA1c.
  • These results from Vida Health are further proof that human-led virtual care solutions can have meaningful and lasting impacts on the health of people with diabetes.
  • These meaningful diabetes outcomes are the latest positive results from Vida published in peer reviewed publications.

Outlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities

Retrieved on: 
Tuesday, May 4, 2021
Diabetes, Organ systems, Health, Diabetes management, Clinical medicine, Journal of Diabetes Science and Technology, Diabetes Australia

b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Needle Free Diabetes Management Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report titled needle free diabetes management market studies various device types such as treatment devices, diagnostic devices and artificial pancreas that respectively sub-segmented.

Key Points: 
  • b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Needle Free Diabetes Management Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report titled needle free diabetes management market studies various device types such as treatment devices, diagnostic devices and artificial pancreas that respectively sub-segmented.
  • According to the International Diabetes Federation, in 2015 one in 11 adult has diabetes and by 2040 it is expected that one in 10 adults will have diabetes.
  • The data suggests that in 2015 every 6 seconds one person dies from diabetes.
  • Thus, diabetes management is one of the most crucial parts to prevent life threatening effects of this disease.